Stan Berenshteyn
Stock Analyst at Wells Fargo
(1.07)
# 3,460
Out of 4,829 analysts
57
Total ratings
41.38%
Success rate
-11.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stan Berenshteyn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TDOC Teladoc Health | Maintains: Equal-Weight | $10 → $8 | $7.11 | +12.52% | 3 | May 8, 2025 | |
| OMCL Omnicell | Maintains: Equal-Weight | $38 → $31 | $25.78 | +20.25% | 14 | May 7, 2025 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $8 → $7 | $4.32 | +62.04% | 8 | Apr 29, 2025 | |
| HQY HealthEquity | Maintains: Overweight | $110 → $125 | $90.44 | +38.21% | 9 | Feb 26, 2025 | |
| DOCS Doximity | Maintains: Equal-Weight | $43 → $55 | $59.19 | -7.08% | 10 | Feb 7, 2025 | |
| HCAT Health Catalyst | Maintains: Overweight | $13 → $10 | $4.13 | +142.13% | 5 | Jan 21, 2025 | |
| AMWL American Well | Upgrades: Overweight | $15 | $6.84 | +119.30% | 3 | Jan 13, 2025 | |
| VEEV Veeva Systems | Maintains: Overweight | $275 → $285 | $237.05 | +20.23% | 5 | Dec 6, 2024 |
Teladoc Health
May 8, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $7.11
Upside: +12.52%
Omnicell
May 7, 2025
Maintains: Equal-Weight
Price Target: $38 → $31
Current: $25.78
Upside: +20.25%
GoodRx Holdings
Apr 29, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $4.32
Upside: +62.04%
HealthEquity
Feb 26, 2025
Maintains: Overweight
Price Target: $110 → $125
Current: $90.44
Upside: +38.21%
Doximity
Feb 7, 2025
Maintains: Equal-Weight
Price Target: $43 → $55
Current: $59.19
Upside: -7.08%
Health Catalyst
Jan 21, 2025
Maintains: Overweight
Price Target: $13 → $10
Current: $4.13
Upside: +142.13%
American Well
Jan 13, 2025
Upgrades: Overweight
Price Target: $15
Current: $6.84
Upside: +119.30%
Veeva Systems
Dec 6, 2024
Maintains: Overweight
Price Target: $275 → $285
Current: $237.05
Upside: +20.23%